Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03129126
Other study ID # Safety and Efficacy of LP-10
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 1, 2020
Est. completion date September 29, 2023

Study information

Verified date March 2023
Source Lipella Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of three doses of LP-10 (intravesical tacrolimus). Twelve subjects meeting the inclusion and exclusion criteria will be enrolled and treated in a prospective and multi-center trial with LP-10. The proposed trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated into each one of three groups.


Description:

This is a multi-center, dose-ranging study including male and female subjects with refractory moderate to severe hemorrhagic cystitis as determined by a physician. A total of up to 12 subjects are anticipated and will be enrolled in study sites in the United States. Enrollment is expected to be completed within one year of initiating the study. The proposed trial will recruit 12 subjects in a dose-escalation trial where 4 subjects will be allocated into each one of three groups.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date September 29, 2023
Est. primary completion date August 21, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Males and females, at least 18 years - History of sterile moderate to severe HC (Grade 2-4) for at least 3 months documented in the medical record with at least 1 episode of macroscopic hematuria with or without clot - Previous use of medications and/or treatment(s) for HC without success - Patients of child-bearing capability agree to use a reliable form of birth control (condoms and/or oral contraceptives) during the course of instillation therapy and for 1 week thereafter - Willing and capable of understanding and complying with all requirements of the protocol, including proper completion of the 3 day Hemorrhagic Cystitis Diary (HC Diary) and self-administered questionnaires Exclusion Criteria: - History of interstitial cystitis/painful bladder syndrome - HC due to infection (bacterial, viral or fungal) - Vesicoureteral reflux disease based on cystogram within past 12 months - Subject is currently or has previously participated in another therapeutic or device study within 3 months of screening and has not returned to baseline - Pregnant or lactating - History of bleeding diathesis or active bleeding peptic ulcer disease - Life expectancy less than 12 months - PSA > 10.0 ng/dl (measured within the last 3 months) - Known allergy to liposomes and/or egg yolk and/or tacrolimus - Urinary retention requiring daily catheterization - Previous augmentation cystoplasty - Subjects currently taking prescribed treatment for HC will be able to continue the treatment throughout the course of the study. If the patient cannot be maintained on a stable dose of the medication(s) throughout the treatment and follow-up period they will be excluded - Subject with history of intravesical treatment(s) within 1 week prior to Study Visit 1 - Sacral and/or pudendal nerve neuromodulation device (Interstim) within the last 6 months. Subjects would not be excluded if they had Interstim greater than 6 months ago and is on a stable setting. - Evidence of renal impairment (creatinine > two times the upper limit of normal at Visit 1), hepatic impairment (AST or ALT > three times the upper limit of normal at Visit 1), clinically significant cardiovascular, respiratory, or psychiatric diseases per investigator's judgment - Post-void residual (PVR) urine volume of > 150 mL at screening - The presence of any clinically significant systemic disease or condition that in the opinion of the investigator would make the patient unsuitable for the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LP-10
Intravesical tacrolimus

Locations

Country Name City State
United States Emory University Atlanta Georgia
United States Baylor College of Medicine Houston Texas
United States Vanderbilt University Medical Center Nashville Tennessee
United States Temple University Philadelphia Pennsylvania
United States Allegheny Health Network Research Institute Pittsburgh Pennsylvania
United States Premier Medical Group Poughkeepsie New York
United States University of California San Francisco San Francisco California
United States Michigan Institute of Urology Troy Michigan
United States University of Arizona Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
Lipella Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient Reported Mean episodes of visible blood Pre-post changes in mean episodes of visible blood in urine (or blood clots) on 3-day bladder diaries at baseline and primary endpoint At every patient visit, up to 2 weeks following initial treatment
Secondary Urine Dipstick Mean episodes of Visible Blood Mean episodes of visible blood in urine (or blood clots) and urine dipstick for quantitative grading of microscopic hematuria on bladder diaries At every patient visit, up to 2 weeks following initial treatment
Secondary Mean urine hemoglobin concentration Mean urine hemoglobin concentration At every patient visit, up to 2 weeks following initial treatment
Secondary Urine analysis with microscopy Urine analysis with microscopy including red blood cells per high power field test At every patient visit, up to 2 weeks following initial treatment
Secondary Whole blood Add to dictionary levels Whole blood tacrolimus levels At every patient visit, up to 2 weeks following initial treatment
Secondary Blood chemistry and liver function test Blood chemistry and liver function test At every patient visit, up to 2 weeks following initial treatment
Secondary Patient Reported Global Response Assessment Survey Score Changes in Global Response Assessment (GRA) At every patient visit, up to 2 weeks following initial treatment
Secondary Patient Reported Urinary frequency Changes in urinary frequency and incontinence measured on diaries At every patient visit, up to 2 weeks following initial treatment
Secondary Bladder Cystoscopy Cystoscopic changes in bladder At initial treatment and on final patient visit, up to 2 weeks following initial treatment
Secondary Patient Reported Health Related Quality of Life Survey Score Changes in Health Related Quality of Life (HRQOL) scores At every patient visit, up to 2 weeks following initial treatment
Secondary Post void residual urine volume Post void residual urine volume At every patient visit, up to 2 weeks following initial treatment
Secondary Patient Reported Pain and Urgency Change in pain and urgency 10 cm visual analog scales (VAS) At every patient visit, up to 2 weeks following initial treatment
Secondary Incidence of Treatment-Emergent Adverse Events Safety data will be collected by ongoing monitoring of adverse events, during the entire duration of the study, including need for blood transfusion, bladder irrigation, emergency room visit, hospitalization, urinary catheterization, and/or surgery in addition to patient reporting of changes in urinary frequency, hematuria/ clots, incontinence, spasm or discomfort. At every patient visit, up to 2 weeks following initial treatment
See also
  Status Clinical Trial Phase
Completed NCT02172963 - A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis Phase 1/Phase 2
Recruiting NCT04696666 - Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis N/A
Recruiting NCT05348239 - Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs Phase 2
Recruiting NCT02174536 - A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis Phase 2
Terminated NCT04390113 - Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC) Phase 3
Not yet recruiting NCT06241274 - Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT N/A
Not yet recruiting NCT06198517 - Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT N/A
Recruiting NCT05726786 - The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial) Phase 3